OR7A10

Across TCGA pan-cancer cohorts, OR7A10 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated OR7A10 data layer compared with 9 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher OR7A10 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated OR7A10 expression acts as an unfavorable survival marker, although some lineages such as LUSC show a favorable association.

LIHC, GBM, and COAD are the cancer types where OR7A10 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Median	All	0.028	0.777	<.001	24	view →
GBM	OS	Median	All	0.105	0.419	.003	6	view →
COAD	DFS	Median	All	0.235	0.790	.010	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
SKCM	OS	Median	All	0.456	0.783	.048	3	view →
LUSC	DFS	Median	All	1.000	0.385	.036	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

OR7A10–LIHC (OS)

Open the LIHC breakdown →